

Advancements in Cancer Research and Therapeutics

March 25–27, 2026

📍 DoubleTree Suites by Hilton Boston Cambridge
400 Soldiers Field Road, Allston, MA, 02134

Bronze Sponsor

AcroCyte



7:30-8:15 On-site Registration / Badge Pickup @Atrium Foyer
8:15-8:30 Introduction & Welcome Remarks

Plenary Session



Moderator
William Gmeiner, Wake Forest University School of Medicine, NC



8:30-9:10
Rakesh K Jain, Harvard Medical School and Massachusetts General Hospital, MA
Improving Immunotherapy of Glioblastoma by Reprogramming the Tumor Microenvironment: Emerging Insights and Strategies



9:10-9:50
Tyler Jacks, MIT, MA
Probing Tumor-Immune Interactions using Genetically Engineered Mouse Models

9:50-10:10 Break and Networking @Atrium Foyer



10:10-10:50
John Quackenbush, Harvard T. H. Chan School of Public Health, MA
Network Transitions as Drivers of Disease



10:50-11:30
Khalid Shah, Harvard Medical School, MA
The Concept of Innovation and Orchestration: Translating Cell Based Immunotherapies from Bench to Bedside



11:30-12:10
Douglas Green, St Jude Children's Research Hospital, TN
Paradigm Shifts in Cell Death Research



12:10-12:50
Ellen Pure, University of Pennsylvania, PA
Strategies to Overcoming Multiple Challenges to CAR T Cell Therapy for the Treatment of Desmoplastic Tumors

12:50-13:50 Group Picture | Lunch & Networking @Roosevelt Room

Session I Cancer Immunology and Immunotherapy

Chairs



Geeta Upadhyay
Uniformed Services University, MD



Lucas Ferrari de Andrade
Icahn School of Medicine at Mount Sinai, NY



13:50-14:30 **Plenary**
Kai Wucherpfennig, Dana-Farber Cancer Institute, Harvard Medical School, MA
Therapeutic Targeting of the Cancer – Immunity Cycle



14:30-15:00 **Keynote**
Xingxing Zang, Albert Einstein College of Medicine, NY
New Immune Pathways: from Fundamental Discoveries to Novel Drugs to New Clinical Trials



15:00–15:20

Alexander Barrow, Doherty Institute, Australia

NK Cell Receptor Signaling in Cancer Immunotherapy: Mechanistic Insights and Therapeutic Potential



15:20–15:40

Lucas Ferrari de Andrade, Icahn School of Medicine at Mount Sinai, NY

Selective Inhibition of Fc Receptor Shedding to Promote Antibody-Dependent Cellular Cytotoxicity against Tumors

15:40–15:50

Break and Networking

@Atrium Foyer



15:50–16:10

Rizwan Romee, Dana Farber Cancer Institute, Boston, MA

Novel NK Cell Immunotherapeutic Approaches to Cancer



16:10–16:30

Jessica Thaxton, University of North Carolina at Chapel Hill, NC

Manipulating the Integrated Stress Response to Fuel Tumor Immunotherapy



16:30–16:50

Geeta Upadhyay, Uniformed Services University, MD

Emerging Biomarkers for Solid Cancer- Immunotherapies



16:50–17:10

Megan L. Burger, Knight Cancer Institute, OR

Therapeutic Vaccination to Remodel Antigen Hierarchies



17:10–17:30

Yina H Huang, Geisel School of Medicine, NH

Contrasting CAR T and Nanoparticle Delivery of Cytokine Immunotherapies



17:30–17:50

Scott H Olejniczak, Roswell Park Comprehensive Cancer Center, NY

CD28 Drives CAR T-Cell Responses in Myeloma and Lymphoma Models



17:50–18:10

Liya Ding, Roswell Park Comprehensive Cancer Center, NY

Preclinical Models and Therapeutic Approaches Targeting Tumor Cells and Immune Suppression in Prostate Cancer



18:10–18:30

Yufei Wang, Dana-Farber Cancer Institute, MA

Engineering the Next Generation of CAR T-Cells for Solid Tumors



18:30–18:50 **Virtual**

TAY Rong En, Singapore Immunology Network, Singapore

Serotonin Receptor 5-HT_{2A} as a Potential Target for HCC Immunotherapy

18:45–19:45

Networking & Drinks

@Atrium Foyer

Session II

Metastasis and Tumor Progression

Chairs



William Gmeiner
Wake Forest University
School of Medicine, NC



Kaifu Chen
Harvard Medical School, MA



8:30-9:10 **Plenary**
Channing J Der, UNC School of Medicine, NC
Targeting KRAS for Cancer Treatment



9:10-9:50 **Plenary**
A Thomas Look, Dana-Farber Cancer Institute, Harvard Medical School, MA
KAT6A/B Inhibitor Enhances GD2-Immunotherapy in High-Risk Neuroblastoma



9:50-10:20 **Keynote**
Joyce Slingerland, Lombardi Comprehensive Cancer Center, DC
High Local Estrone Impairs Antitumor Immunity to Drive Obesity-Associated Breast Cancer Progression

10:20 -10:30

Break and Networking

@Atrium Foyer



10:30-10:50
Rizwan Haq, Dana-Farber Cancer Institute, MA
New Models of Metastatic Uveal Melanoma to Uncover Therapeutic Targets



10:50-11:10
Blake R. Wilde, Roswell Park Comprehensive Cancer Center, NY
Metabolic Determinants of Kidney Cancer Initiation



11:10-11:30
Hyungshin Yim, Hanyang University, South Korea
PLK1 Signaling Network as a Driver of Metastasis in NSCLC



11:30-11:50
Christina M. Ferrer, University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, MD
Slow-Cycling, Glutathione-Sensing GSTT1⁺ Cells Mediate Therapy Resistance and Metastasis in Pancreatic Cancer



11:50-12:10
William Gmeiner, Wake Forest University School of Medicine, NC
Improving Efficacy and Overcoming Resistance in Treatment of Liver-Metastatic Colorectal Cancer with CF10



12:10-12:30
Kaifu Chen, Harvard Medical School, MA
Nanopore Sequencing Reveals Alternative Polyadenylation Regulated by RNA Modification in Prostate Cancer



12:30-12:50
Oliver Bogler, Coaching and Consulting, VT
NIH Grants Update and How to Compete in 2026?

12:50–14:00

Lunch & Networking

@Roosevelt Room

Session III

Drug Discovery and Novel Therapeutics

Chairs



Lee Graves
University of North
Carolina, NC



Hernando Lopez Bertoni
Johns Hopkins School of Medicine
MD



14:00–14:20

Lee Graves, University of North Carolina, NC
Application of Novel ClpP Agonists for Cancer Treatment



14:20–14:40

Deepak Veeregowda, QT Sense, Netherlands
Real-Time Measurements of Free Radicals in Living Cancer Cells and Mitochondria



14:40–15:00

Richard Kolesnick, Memorial Sloan Kettering Cancer Center, NY
ENT1 Dimerization in a Ceramide-Rich Platform Enhances Gemcitabine Uptake
Improving Sarcoma Patient Response Rate



15:00–15:20

Hernando Lopez Bertoni, Johns Hopkins School of Medicine, MD
Resistance is Futile: Collapsing Networks to Outmaneuver GBM



15:20–15:40

Leif W. Ellisen, MGH Cancer Center, Harvard Medical School, MA
Targeting Metabolic Reprogramming Underlying Therapy Resistance in TNBC

15:40–15:50

Break and Networking

@Atrium Foyer



15:50–16:10

Grant Fischer, UNC School of Medicine, NC
Integrative Bioinformatics and Experimental Insights into Melanoma Pathology



16:10–16:30

Gamze Ayaz, NIDDK/NIH, MD
Thyclotide-Peptide Conjugates Enable Efficient Cellular Delivery and Reactivate
p53 by Disrupting MDM2 Interaction in Cancer Cells



16:30–16:50

Morgan M. Eikanger, University of South Dakota, SD
Veratridine Suppresses the Rictor-mTORC2 Signaling Pathway to Inhibit
Metastatic Colon Cancer



16:50–17:10

Zeinaf Muradova, Brigham and Women's Hospital and Dana-Farber Cancer
Institute, MA
Gadolinium-Based Theranostic Nanoparticles as Immunomodulators in
Cancer Models



17:10–17:30

Audrey Van Heest, Boston University, MA
Engineering Protease-Responsive Biosensors for Precision Oncology

Session IV Cancer Biology, Targeted Therapies & Tumor Microenvironment

Chair



Blake R. Wilde
Roswell Park Comprehensive Cancer Center, NY



8:00-8:30 **Keynote**
Peter Caravan, Massachusetts General Hospital, MA
Non-Invasive Imaging of the Tumor Microenvironment to Monitor Treatment Response



8:30-8:50
J. Javier Bravo-Cordero, Icahn School of Medicine at Mount Sinai, NY
The Textures of the Tumor Microenvironment: An Integrated Imaging Perspective



8:50-9:10
Asaf Rotem, AstraZeneca, MA
Multimodality of Single Cell Analysis in Clinical Settings



9:10-9:30
Yunqing Li, Hugo W. Moser Research Institute at Kennedy Krieger, MD
Targeting Tumor Cell Intrinsic Epigenetic Determinants in Brain Tumors



9:30-9:50
Carrie D. House, San Diego State University, CA
Chemotherapy-Induced NF- κ B Activation Drives Stress Tolerance and Relapse in Ovarian Cancer

9:50-10:00

Break and Networking

@Atrium Foyer



10:00-10:20
Jennifer M Binning, Moffit Cancer Center, FL
Engineering Targeted Degradors of the HPV Oncoprotein E6



10:20-10:40
Mutlay Sayan, Harvard Medical School, MA
Defining the Role of Whole-Pelvis Radiotherapy in Modern Prostate Cancer Care



10:40-11:00
Allison Fitzgerald, Dana Farber Cancer Institute, MA
Strategies to Enhance Cell Therapy Infiltration into Solid Tumors



11:00-11:20
Analisa DiFeo, University of Michigan, MI
Therapeutic Inhibition of Oncogenic miR-181a Processing for Cancer Therapy



11:20-11:40
Allegra A. Petti, Massachusetts General Hospital, MA
Integrating Spatial and Single-Cell Transcriptomics to Resolve the Spatial Organization of Glioblastoma



11:40–12:00

Louise Treanor, Novartis Institutes for BioMedical Research, MA
How DLBCL Outsmarts CD19 CAR T Cells: Cross-Antigen Escape, Resistance, and the Gene Signature Predictive of Clinical CAR T-cells Response



12:00–12:25 **Keynote**

David Liu, Dana Farber Cancer Institute, MA
Clinical and Genomic Correlates of Organotropism in Metastatic Melanoma



12:25–12:40

Mohammad Nikmaneshi, Harvard Medical School and Massachusetts General Hospital, MA
Mathematical Modeling of Cancer–T Cell Interactions to Boost Anti-Cancer Immunity

12:40–13:40

Lunch

@Roosevelt Room

Virtual Session

Chair



Stefanie Galban
University of Michigan, MI

13:00–13:20

Stefanie Galban, University of Michigan, MI
Identification of Tumor Microenvironment-Dependent Resistance and Emergence of Persister Cells to KRAS Inhibition in Lung Cancer

13:20–13:40

Victor Peperzak, University Medical Center Utrecht, The Netherlands
Enhancing CAR T-Cell Cytotoxicity Against Multiple Myeloma Through Targeted Cargo Delivery

13:40–14:00

Owen Moon, Immunokey Ltd, UK
CARKey™ – A Multi-Specific CAR T-Cell Platform to Overcome Solid Tumor Antigen Heterogeneity

14:00–14:20

Minji Jung, Stanford University, CA
Bidirectional Links Between Kidney Cancer and Cardiovascular Disease: Emerging Epidemiologic Insights

14:20–14:40

Mostafa Ibrahim, University of Michigan, MI
Inducible and Reversible H3K27M Models to Define Oncohistone-Driven Epigenome and Tumor Microenvironment (TME) Remodeling in Diffuse Midline Glioma

14:40–15:00

Angus Gordon, Imperial College Healthcare Trust, London, UK
Tumor Volume Analysis Applied to Breast Cancer

Closing Remarks of Conference and Announcement of 2027 Edition

We wish to see you at

ACRT – 2027

November 2027 | Boston, MA

Organized By



IRC
Impact Research Communications

 **Impact Research Communications**

#3, Bonaire Drive, Dix Hills, NY, 11746

 +1 929 999 7374

 committee@acrtconference.org

 www.acrt.ircconferences.net